Clinical Trial Update: Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating tasimelteon versus placebo for sleep disturbances in Smith-Magenis Syndrome and circadian-related conditions; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Circadian Rhythm Sleep Disorders
• Smith-magenis Syndrome

Drugs mentioned

• Tasimelteon (tasimelteon)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Smith-Magenis Syndrome, Circadian | Phase 2, Phase 3 | Status: COMPLETED